1. Home
  2. GGAL vs RYTM Comparison

GGAL vs RYTM Comparison

Compare GGAL & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grupo Financiero Galicia S.A.

GGAL

Grupo Financiero Galicia S.A.

HOLD

Current Price

$49.72

Market Cap

6.6B

Sector

Finance

ML Signal

HOLD

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$83.88

Market Cap

6.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GGAL
RYTM
Founded
1905
2008
Country
Argentina
United States
Employees
10079
N/A
Industry
Commercial Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.6B
6.2B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
GGAL
RYTM
Price
$49.72
$83.88
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
14
Target Price
$69.00
$131.14
AVG Volume (30 Days)
1.3M
692.5K
Earning Date
03-07-2023
05-05-2026
Dividend Yield
3.70%
N/A
EPS Growth
N/A
28.34
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$62.29
$55.34
Revenue Next Year
$22.88
$86.06
P/E Ratio
$13.36
N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.89
$60.71
52 Week High
$62.11
$122.20

Technical Indicators

Market Signals
Indicator
GGAL
RYTM
Relative Strength Index (RSI) 63.42 41.68
Support Level $47.86 $82.31
Resistance Level $50.20 $90.79
Average True Range (ATR) 2.07 3.80
MACD 1.07 -0.60
Stochastic Oscillator 81.51 7.57

Price Performance

Historical Comparison
GGAL
RYTM

About GGAL Grupo Financiero Galicia S.A.

Grupo Financiero Galicia SA is a financial service holding company. It provides general banking services, proprietary brand credit card services, personal loans, insurance, and other services. The company's operating business segments are Banks, Ecosistema Naranja X, Insurance, Adjustments, and Other Businesses. The company generates maximum revenue from Banks. Geographically its operate in Argentina, Uruguay, and the majority of its revenue comes from Argentina.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Share on Social Networks: